Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
RxSight ( (RXST) ) has issued an announcement.
On January 11, 2026, RxSight reported preliminary unaudited results indicating fourth-quarter 2025 revenue of about $32.6 million and full-year 2025 revenue of roughly $134.5 million, exceeding its prior guidance. Growth was driven by the sale of 28,611 Light Adjustable Lenses in the fourth quarter and 109,615 lenses for the year, alongside 25 Light Delivery Devices in the quarter and 163 for the year, bringing the installed base to 1,134 devices and supporting an estimated 10% share of the premium intraocular lens market and adoption by more than a quarter of U.S. cataract surgeons. The company ended 2025 with an expected $228.1 million in cash, cash equivalents and short-term investments, positioning it with significant financial flexibility as it prepares to release audited full-year 2025 results and 2026 guidance in February. In tandem with these results, RxSight completed its planned finance leadership transition: on December 13, 2025, it appointed former Edwards Lifesciences executive Mark Wilterding as Chief Financial Officer, effective January 11, 2026, replacing Shelley Thunen, and granted him a compensation package including salary, bonus eligibility, equity awards, and change-in-control severance terms aligned with other senior executives, reinforcing the company’s leadership bench as it pursues long-term growth in the premium cataract surgery market.
The most recent analyst rating on (RXST) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on RxSight stock, see the RXST Stock Forecast page.
Spark’s Take on RXST Stock
According to Spark, TipRanks’ AI Analyst, RXST is a Neutral.
RxSight’s overall stock score is primarily influenced by its financial challenges, including negative profitability and revenue decline. While technical indicators show some positive momentum, the valuation remains unattractive due to the negative P/E ratio. The earnings call provided mixed signals with improvements in certain areas but highlighted significant revenue and net loss challenges.
To see Spark’s full report on RXST stock, click here.
More about RxSight
RxSight, Inc. is an ophthalmic medical device company focused on providing customized vision to patients following cataract surgery. Its core product, the RxSight Light Adjustable Lens system—comprising the Light Adjustable Lens and Light Delivery Device—is the first and only commercially available intraocular lens technology that can be adjusted after surgery, targeting the premium intraocular lens segment and serving a growing base of U.S. cataract surgeons.
Average Trading Volume: 756,898
Technical Sentiment Signal: Sell
Current Market Cap: $393.5M
See more insights into RXST stock on TipRanks’ Stock Analysis page.